Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
a study on Liver Disease
Summary
- Eligibility
- for females ages 18-45 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- Dr. Monika Sarkar
Description
Summary
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
Official Title
Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS)
Details
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS. \
The study will be conducted over a period of up to 34 weeks and will include Screening (Days -28 to -7) Phase, a 24-week Treatment Phase following randomization on Day 1.
The primary endpoint of the study is change in hepatic fat content from baseline following 24 weeks of treatment as measured by MRI-PDFF.
Keywords
Non-alcoholic Fatty Liver Disease in Women With PCOS NAFLD PCOS Saroglitazar Magnesium Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Saroglitazar Magnesium 4 mg Tablet Saroglitazar Magnesium 4 mg
Eligibility
You can join if…
Open to females ages 18-45
- Females, 18 to 45 years of age.
- Previously confirmed diagnosis of PCOS:
- oligo-and/or anovulation;
- hyperandrogenism (clinical and/or biochemical);
- polycystic ovary morphology on ultrasonography
- Evidence of NAFLD within 6 months prior to the Screening Visit (Visit 1).
- Hepatic fat fraction ≥10% by MRI-PDFF.
- Willingness to participate in the study.
- Ability to understand and give informed consent for participation.
- Woman who agrees to use the contraceptive methods.
You CAN'T join if...
- Presence of other chronic liver diseases (hepatitis B or C, autoimmune hepatitis, cholestatic liver disease, Wilsons disease, hemochromatosis, etc.).
- Average alcohol consumption ≥ 7 drinks per week for women in the 6 months prior to enrollment.
- Clinical, imaging, or histological evidence of cirrhosis.
- Patients who have used medications known to cause hepatic steatosis for more than 2 weeks in the past year.
- Prior bariatric surgery.
- Weight loss of more than 5% in the 3 months preceding screening.
- Severe co-morbidities (e.g., advanced cardiac, renal, pulmonary, or psychiatric illness).
- Known allergy, sensitivity or intolerance to Saroglitazar Magnesium, comparator or formulation ingredients.
- Use of antidiabetic and lipid lowering medications if the dose is not stable for at least the 3 months preceding screening.
- Intake of Vitamin E (>100 IU/day) or multivitamins containing Vitamin E (>100 IU/day) 3 months before enrollment.
- Use of drugs with potential effect on NAFLD/NASH in the 3 months prior to screening.
- Illicit substance abuse within the past 12 months.
- Pregnant or breast feeding females.
- Women with known Cushing syndrome or hyperprolactinemia.
- Refusal or inability to comply with the requirements of the protocol, for any reason, including scheduled clinic visits and laboratory tests.
- History of myopathies or evidence of active muscle diseases.
- History or current significant cardiovascular disease.
- History of malignancy.
- History of bladder disease.
Locations
- University of California, San Francisco
accepting new patients
San Francisco California 94143 United States - Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C.
not yet accepting patients
Culiacán Sinaloa 80230 Mexico
Lead Scientist at UCSF
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Zydus Discovery DMCC
- ID
- NCT03617263
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03617263.